Biomarkers of palbociclib response in hormone receptor-positive advanced breast cancer from the PARSIFAL trial

Biomarkers of palbociclib response in hormone receptor-positive advanced breast cancer from the PARSIFAL trial

Abstract Currently, there are no clinically actionable biomarkers to predict patient to cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i) plus endocrine therapy for hormone receptor (HR)[+]/ human epidermal growth factor receptor 2 (HER2)[-] advanced breast cancer (ABC). Herein, we report an exp...

Full description

Saved in:

Bibliographic Details
Main Authors:	Joan Albanell, Angelo Gámez Pozo, Carlos L. Arteaga, Meritxell Bellet, Federico Rojo, Abel González, Beatriz Bellosillo, Violeta Serra, Petra Gener, José Antonio Guerrero, Eileen Shimizu, Mario Mancino, Jose Rodríguez-Morató, Leonardo Mina, José Manuel Pérez-García, Javier Cortés, Antonio Llombart-Cussac
Format:	Article
Language:	English
Published:	Nature Portfolio 2025-06-01
Series:	npj Breast Cancer
Online Access:	https://doi.org/10.1038/s41523-025-00777-0
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

La Mosaïque Parsifal : tome 1 /
by: Ludlum, Robert
Published: (1982)

Patterns of immune evasion in triple-negative breast cancer and new potential therapeutic targets: a review
by: Lucía Serrano García, et al.
Published: (2024-12-01)

Condução de revisões sistemáticas de literatura mediada pela ferramenta Parsif.al: potencialidades e limites
by: Gustavo Carvalho Mauricio, et al.
Published: (2025-05-01)

Palbociclib as an Antitumor Drug: A License to Kill
by: Agnieszka Łupicka-Słowik, et al.
Published: (2024-11-01)

Neutropenia due to palbociclib: A word of caution?
by: Raja Pramanik, et al.
Published: (2016-01-01)

Microdynamic flowability for early API characterisation: A case study on Palbociclib
by: David Blanco, et al.
Published: (2025-12-01)

Letrozole and palbociclib in advanced breast cancer: Outcome from cancer institute, Chennai
by: Vijay Gnanaguru, et al.
Published: (2020-01-01)

Enhancing palbociclib efficacy with low toxicity in breast cancer using polycaprolactone-based nanocarriers
by: Nastaran Zerang, et al.
Published: (2025-05-01)

Surface functionalized albumin nanoparticles of palbociclib with amplified brain delivery for treating brain glioblastoma
by: Vishwanath Kurawattimath, et al.
Published: (2025-08-01)

¡Cómo hemos cambiado! Mutaciones del derecho penal
by: José L. González Cussac
Published: (2023-06-01)

¡Cómo hemos cambiado! Mutaciones del derecho penal
by: José L. González Cussac
Published: (2023-06-01)

CYCLIN-DEPENDENT KINASE INHIBITOR, PALBOCICLIB – A NEW DRUG FOR THE TREATMENT OF METASTATIC BREAST CANCER
by: E. N. Imyanitov, et al.
Published: (2017-12-01)

CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib
by: Eric Raspé, et al.
Published: (2017-05-01)

Cost-effectiveness Analysis of Ribociclib plus Letrozole versus Palbociclib plus Letrozole in the United Kingdom
by: Gaurav Suri, et al.
Published: (2019-04-01)

Investigation of ribociclib, abemaciclib and palbociclib resistance in ER+ breast cancer cells reveal potential therapeutic opportunities
by: Mashael Algethami, et al.
Published: (2025-08-01)

Real-world effectiveness of palbociclib in HR+/HER2- metastatic breast cancer: a literature review
by: Emilie Adrian Christiansen, et al.
Published: (2024-12-01)

Population Pharmacokinetic and Pharmacodynamic Study of Palbociclib in Children and Young Adults with Recurrent, Progressive, or Refractory Brain Tumors
by: John C. Panetta, et al.
Published: (2024-11-01)

mmunohistochemistry of the new molecular classification of breast carcinoma and its prognostic and therapeutic implications
by: Antonio Llombart Bosch
Published: (2012-12-01)

Palbociclib and dsRNA sensor co-operate to enhance anti-cancer effects through ER stress and modulation of immune evasion
by: Victoria Roulstone, et al.
Published: (2025-05-01)

CD4+ lymphocytopenia and Pneumocystis jirovecii pneumonia in a metastatic breast cancer patient treated with palbociclib and corticosteroids
by: Shahar Dekel, et al.
Published: (2025-07-01)

Targeting ferroptosis resistance resensitizes metastatic HR+HER2− breast cancer cells to palbociclib‐hormone therapy
by: Charles Pottier, et al.
Published: (2025-04-01)

Cisplatin palbociclib combination differentially modulates PTEN AKT signaling via Hsp90 in hepatocellular carcinoma cells
by: Hameis M. Sleem, et al.
Published: (2025-06-01)

Real-world effectiveness of palbociclib plus an aromatase inhibitor in HR+/HER2− MBC patients living in disadvantaged neighborhoods
by: Filipa Lynce, et al.
Published: (2025-07-01)

Cyclin-Dependent Kinase 4/6 Inhibitor (Palbociclib) Induced Aplastic Anemia in a Patient with Metastatic Breast Cancer
by: Stanley Madu Nwabudike, et al.
Published: (2018-01-01)

Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy
by: Sonia Pernas, et al.
Published: (2024-11-01)

LA MODALIDAD EPISTÉMICA ASERTIVA COMO RECURSO RETÓRICO EN NOTICIAS CIENTÍFICAS: EL CASO DEL HALLAZGO PALEONTOLÓGICO DEL HOMBRE DE ORCE
by: José Antonio Díaz Rojo
Published: (2007-05-01)

Terminología médica, cultura e ideología
by: José Antonio Díaz Rojo
Published: (2005-12-01)

Author Correction: Palbociclib and dsRNA sensor co-operate to enhance anti-cancer effects through ER stress and modulation of immune evasion
by: Victoria Roulstone, et al.
Published: (2025-07-01)

PALBOCICLIB IN COMBINATION WITH HORMONE THERAPY FOR LUMINAL HER2-NEGATIVE METASTATIC BREAST CANCER: NEW HIGHLY EFFECTIVE STRATEGY OF DRUG TREATMENT
by: E. V. Artamonova
Published: (2017-09-01)

TMEM45A enhances palbociclib resistance and cellular glycolysis by activating AKT/mTOR signaling pathway in HR+ breast cancer
by: Cui Chen, et al.
Published: (2025-02-01)

Overall Survival With Palbociclib and Aromatase Inhibitor Versus Aromatase Inhibitor Alone in Older Patients With HR+/HER2− Metastatic Breast Cancer
by: Adam M. Brufsky, et al.
Published: (2025-04-01)

The Effectiveness of Ozone Infiltration on Patient-Reported Outcomes in Low Back Pain: A Systematic Review and Meta-Analysis
by: Rafael Llombart-Blanco, et al.
Published: (2024-10-01)

Healthcare Resource Utilization and Cost Comparison Between Palbociclib, Abemaciclib, and Ribociclib Among Patients with HR+/HER2− Metastatic Breast Cancer
by: Pluard TJ, et al.
Published: (2025-03-01)

Clinical Benefit and Safety of Palbociclib in Hormone Positive Breast Cancer with Visceral Metastasis: Real-World Experience from a Tertiary Cancer Center
by: Sandeep K. S, et al.
Published: (2025-04-01)

Palbociclib-induced Toxic Epidermal Necrolysis: A Case Report with Review of All Cases Secondary to Cyclin-dependent Kinase 4/6 Inhibitors
by: Aurore Devoldere, et al.
Published: (2025-01-01)

Présentation
by: Francisco Bellosillo, et al.
Published: (2011-04-01)

Weight-Bearing Versus Non-Weight-Bearing After Ankle Fracture: A Systematic Review and Meta-Analysis of Patient-Reported Outcome
by: Rafael Llombart-Blanco, et al.
Published: (2025-02-01)

WCN25-625 ASSESSING RENAL FUNCTION IN PATIENTS UNDERGOING TARGETED CANCER THERAPIES: THE ROLE OF CYSTATIN C IN PALBOCICLIB-INDUCED SERUM CREATININE ELEVATION
by: Kais Harzallah
Published: (2025-02-01)

Real-world palbociclib dose modifications and clinical outcomes in patients with HR+/HER2− metastatic breast cancer: A Flatiron Health database analysis
by: Rachel M. Layman, et al.
Published: (2025-06-01)

The Vital Dynamism of the Voice in Diderot
by: Hélène Cussac
Published: (2016-06-01)